Compare PROV & SLDB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PROV | SLDB |
|---|---|---|
| Founded | 1956 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 103.7M | 759.8M |
| IPO Year | 2009 | 2017 |
| Metric | PROV | SLDB |
|---|---|---|
| Price | $17.06 | $7.15 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 11 |
| Target Price | $16.25 | ★ $16.36 |
| AVG Volume (30 Days) | 6.2K | ★ 965.3K |
| Earning Date | 04-28-2026 | 05-12-2026 |
| Dividend Yield | ★ 3.26% | N/A |
| EPS Growth | N/A | ★ 34.97 |
| EPS | ★ 0.68 | N/A |
| Revenue | N/A | ★ $8,094,000.00 |
| Revenue This Year | $4.14 | N/A |
| Revenue Next Year | $3.70 | N/A |
| P/E Ratio | $25.07 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $14.85 | $2.61 |
| 52 Week High | $17.42 | $8.87 |
| Indicator | PROV | SLDB |
|---|---|---|
| Relative Strength Index (RSI) | 56.17 | 45.21 |
| Support Level | $16.93 | $6.58 |
| Resistance Level | $17.38 | $7.33 |
| Average True Range (ATR) | 0.21 | 0.45 |
| MACD | -0.04 | -0.02 |
| Stochastic Oscillator | 31.48 | 34.10 |
Provident Financial Holdings Inc is a holding company of Provident Savings Bank, F.S.B. It is a financial services company committed to serving consumers and small to mid-sized businesses in the Inland Empire region of Southern California. Its business activities consist of community banking, investment services and trustee services for real estate transactions. The group operates in Bank segment that include attracting deposits, offering banking services and originating and purchasing single-family, multi-family, commercial real estate, construction and, to a lesser extent, other mortgage, commercial business and consumer loans. Its evenues are derived from interest earned on its loan and investment portfolios, and fees generated through its community banking activities.
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.